Press release
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":" FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting its portfolio of skin cancer gene expression profile (GEP) tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology (AAD) Annual Meeting, being held March 17-21 in New Orleans.\n\n“At Castle, we believe our tests help clinicians make more informed decisions in the care of patients with skin cancers,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “As such, we focus strongly on continued evidence development to demonstrate where our tests can add value to clinical decision-making to improve outcomes for patients. In collaboration with leading physicians across the U.S., we are proud to present new data at this year’s AAD meeting highlighting the utility of our dermatologic tests as part of our commitment to advancing patient care.”\n\nFollowing are details for the four abstracts that were accepted at AAD. Abstract content for the ePosters will be available in the online viewing portal beginning the first day of the meeting and on-site using the computers at the Poster Exhibit Presentation Center. They will also be published online via the JAAD supplement in Fall 2023.\n\nDecisionDx®-SCC\nLate-breaking oral presentation title: The 40-gene expression profile (40-GEP) continues to demonstrate independent metastatic risk stratification and improved accuracy in risk assessment in a novel cohort of cutaneous squamous cell carcinoma (cSCC) patients with one or more risk factors\nPresenter and Lead Author: Ashley Wysong, M.D., M.S., Department of Dermatology, University of Nebraska Medical Center\nDate: March 18, 2023\nTime: 3:40-3:50 p.m. Central time\nLocation: New Orleans Ernest N. Morial Convention Center, Theater B\n\nePoster title: Clinicians’ use of the 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (SCC) patients is consistent with intended use parameters\nLead Author: Gaurav Singh, M.D., Milwaukee\nAbstract Number: 44006\n\nDecisionDx®-Melanoma\nePoster title: The 31-gene expression profile test for cutaneous melanoma identifies patients with stage IB-IIA disease who have re...